Background -A viral cause of idiopathic pulmonary fibrosis (IPF) was recently suggested by a Japanese study in which a high prevalence ofanti-hepatitis C virus (HCV) antibodies was detected. A subsequent British study failed to confirm these results. Methods -Antibodies to HCV were evaluated in 60 patients with IPF, 130 patients with non-interstitial lung disease, and in 4614 blood donors. HCV-RNA and HCV genotypes were evaluated in the anti-HCV positive patients with IPF. Anti-HCV antibodies were evaluated by ELISA and confirmed by recombinant inumunoblotting assay (RIBA). HCV-RNA and genotypes were detected by reverse transcriptase polymerase chain reaction (PCR). Results -Eight patients with IPF had anti-HCV antibodies detected by ELISA (13.3%). In the blood donor control group the prevalence of HCV antibodies was
Background -A viral cause of idiopathic pulmonary fibrosis (IPF) was recently suggested by a Japanese study in which a high prevalence ofanti-hepatitis C virus (HCV) antibodies was detected. A subsequent British study failed to confirm these results. Methods -Antibodies to HCV were evaluated in 60 patients with IPF, 130 patients with non-interstitial lung disease, and in 4614 blood donors. HCV-RNA and HCV genotypes were evaluated in the anti-HCV positive patients with IPF. Anti-HCV antibodies were evaluated by ELISA and confirmed by recombinant inumunoblotting assay (RIBA). HCV-RNA and genotypes were detected by reverse transcriptase polymerase chain reaction (PCR). Results -Eight patients with IPF had anti-HCV antibodies detected by ELISA (13.3%). In the blood donor control group the prevalence of HCV antibodies was lower (0.3%). In patients with non-interstitial lung disease HCV antibody prevalence was 6-1%. In all eight patients with IPF found to be anti-HCV positive by ELISA, HCV antibodies were also detected by RIBA The prevalence of anti-HCV antibodies in the IPF and control groups was compared using the x2 test.
Results
Eight of the 60 patients with IPF were positive for anti-HCV as detected by ELISA (13X3%), a significantly higher prevalence than that obtained in the blood donor group (14/4614, 0-3%, p<00001). Anti-HCV antibodies were found in eight of 130 patients (6 1 %) with noninterstitial lung disease. No clustering of the anti-HCV positive patients in a single diagnostic group was observed. This prevalence is significantly higher than that of blood donors (p<00001) but is not significantly different from that of the patients with IPF. While no risk factor for HCV infection was present in patients with IPF, five of these eight anti-HCV positive patients had major risk factors (four had received multiple transfusions and one was an intravenous drug abuser) and two had a history of surgical treatment.
All eight anti-HCV positive patients with IPF were also positive for two or more antigens by the RIBA (table) , and all had circulating HCV-RNA detected by RT/PCR.
HCV genotypes were identified in four patients. All were type II positive and two were also infected with genotypes III and IV. Genotypes were unidentified in the remaining four cases (table) .
At the time of the viral investigations five of the eight patients had mild biochemical signs of liver disease which fluctuated both before and after the viral studies. Three other patients did not show elevated transaminase values either before or after HCV-RNA detection. Liver biopsy was performed in only one patient and showed chronic active hepatitis.
Discussion
The determination of anti-HCV antibodies in the serum samples of our Italian patients with IPF confirms the results obtained in Japan.3 Furthermore, all anti-HCV positive patients were also positive for HCV-RNA, indicating active HCV replication in 13-3% of patients with IPF. Irving et al did not find a significant increase in anti-HCV antibodies in their series and suggested either geographical differences in the aetiology of IPF or false positive tests in the Japanese study. Possible false positives were ascribed to the poor specificity of first generation screening ELISA for anti-HCV and the interference ofhigh levels of IgG in patients with IPF. We used a second generation ELISA and the results obtained with RT/PCR stressed the specificity of our anti-HCV antibody tests. There is a discrepancy between our results and the negative British study although the two patient populations appeared to be clinically similar. Geographical difference may be a factor. Indeed, the prevalence of HCV infection is high in Japan and Mediterranean countries and low in Northern Europe. The prevalence of anti-HCV antibodies in our series was higher than in the blood donor control group, but these subjects do not represent the most appropriate control group as they were younger and had a selection bias. People who volunteer as blood donors are generally not at risk for hepatitis viruses; however, the prevalence of HCV has recently been documented in the general population of Northern Italy at 3-2% which is lower than that found in patients with IPF.'0
The high prevalence of HCV infection found in patients with IPF is similar to that in the group with other lung diseases. It should be noted that we did not determine HCV-RNA in this group and, among the eight positive cases, five had major and two had minor risk factors for hepatitis C whereas none of the HCV positive patients with IPF had risk factors. A common feature in the two groups (IPF and other lung diseases) is a history of multiple hospital admissions which could be an additional risk factor for HCV infection."1
The study of HCV genotypes provided three points. Firstly, in four of eight patients the genotype was not identified, perhaps due to as yet unclassified genotypes, but the prevalence of indeterminate genotypes is very low in patients who have not had multiple transfusions"2. Secondly, all four patients in whom genotypes were identified had genotype II alone or in combination with other types, and the high frequency of type II genotype is in keeping with the prevalence in Italy.'3 Thus, HCV infection in patients with IPF is not associated with specific genotypes. Thirdly, in two patients a combination of two and three genotypes was present, a rare association in a single patient and almost exclusively confined to cases who have received multiple transfusions. '2 This work was in part supported by grant "ex-60%" from Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MURST) to Riccardo Meliconi.
Background -It can be difficult to assess bronchial responsiveness in children because of their inability to perform spirometric tests reliably. In bronchial challenges lung sounds could be used to detect the required 20% fall in the forced expiratory volume in one second (FEVy).
A study was undertaken to determine whether a change in lung sounds corresponded with a 20% fall in FEV, after methacholine challenge, and whether the occurrence of wheeze was the most important change. Methods -Fifteen children with asthma (eight boys) of mean age 10-8 years (range 8-15) were studied. All had normal chest auscultation before the methacholine challenge test. Lung sounds were recorded over the trachea for one minute and stored on tape. They were analysed directly and also scored blindly from the tape recording by a second investigator. Wheeze, cough, increase in respiratory rate, and prolonged expiration were assessed. Results -The total cumulative methacholine dose causing a fall in FEV1 of 20% or more (PD20) was detected in 12 children by a change in lung sounds -in four by wheeze and in eight by cough, increased respiratory rate, and/or prolonged expiration. In two subjects altered lung sounds were detectable one dose step before PD20 was reached. In three cases in whom no fall in FEV, occurred, no change in lung sounds could be detected at the highest methacholine dose. Conclusion -Changes in lung sounds correspond well with a 20% fall in FEV1 after methacholine challenge. Wheeze is an insensitive indicator for assessing bronchial responsiveness. Cough, increase in respiratory rate, and prolonged expiration occurs more frequently. Measurement of bronchial responsiveness to methacholine has been useful in the diagnosis, assessment of severity, and follow up of asthma, but some children are not able to perform spirometric tests reliably.' A method based on detecting audible wheeze over the trachea and requiring passive cooperation only has been described for bronchial challenge with methacholine in children. 2 In older children a close correlation has been observed between the 20% fall in forced expiratory volume in one second
